Scarica l'app Stockscreener
11.75
1.91%
0.22
Dopo l'orario di chiusura:
11.75
Precedente Chiudi:
$11.53
Aprire:
$11.47
Volume 24 ore:
826.94K
Relative Volume:
1.40
Capitalizzazione di mercato:
$765.35M
Reddito:
$62.71M
Utile/perdita netta:
$-112.51M
Rapporto P/E:
-7.7815
EPS:
-1.51
Flusso di cassa netto:
$-96.01M
1 W Prestazione:
+6.82%
1M Prestazione:
-7.63%
6M Prestazione:
-10.78%
1 anno Prestazione:
+32.77%
Intervallo 1D:
$11.34
$12.15
Intervallo di 1 settimana:
$10.69
$12.15
Portata 52W:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Confronta ZYME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
11.75 | 765.35M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development - The Financial World
Zymeworks appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development - MediaNews4U
Zymeworks Strengthens Clinical Leadership with New Senior VP Appointment - TipRanks
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development | ZYME Stock News - GuruFocus
Zymeworks Strengthens Cancer Drug Pipeline: Top Oncology Expert Takes Helm of Clinical Development - Stock Titan
Major Investment Alert: Ecor1 Capital Boosts Stake in Zymeworks! - TipRanks
Zymeworks to Announce Q1 2025 Financial Results and Host Conference Call - TipRanks
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 | ZYME Stock News - GuruFocus
Zymeworks Inc. to Announce First Quarter 2025 Financial Results on May 8, 2025 - Nasdaq
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewswire
Clinical-Stage Biotech Zymeworks Sets Q1 2025 Earnings Date: Key Updates Expected - Stock Titan
Zymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout - Yahoo Finance
20 Stocks Insiders Bought in April After Trump’s Tariff Rollout - Insider Monkey
Zymeworks sees $3.62 million stock purchase by EcoR1 Capital - Investing.com Canada
Zymeworks Announces Participation in Upcoming Investor Conferences, Business Wires News - AsiaOne
Zymeworks Inc. sees insider purchases totaling $1.5 million By Investing.com - Investing.com UK
Major Investment Alert: Director Buys Big in Zymeworks! - TipRanks
Zymeworks Inc. sees insider purchases totaling $1.5 million - Investing.com
Ecor1 Capital, Llc Purchases 22,689 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Major Investment Alert: Ecor1 Capital Buys Big in Zymeworks! - TipRanks
Ecor1 Capital’s Oleg Nodelman buys $1.23 million in Zymeworks stock By Investing.com - Investing.com Canada
Zymeworks to Engage Investors at Upcoming Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Clinical-Stage Biotech Zymeworks Reveals New Pipeline Insights at Two Major Healthcare Conferences - Stock Titan
Zymeworks to Present Promising Cancer Therapy Data at AACR Meeting - TipRanks
Zymeworks to Present Preclinical Data on T cell Engager and - GlobeNewswire
Game-Changing Cancer Drug Results: Zymeworks Reveals 6 Promising Treatments at AACR - Stock Titan
Zymeworks Inc. (ZYME): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
EcoR1 Capital, LLC Increases Stake in Zymeworks Inc - GuruFocus
Zymeworks Inc. sees $1.64 million stock purchase by EcoR1 Capital - Investing.com Philippines
EcoR1 Capital, LLC's Strategic Acquisition of Zymeworks Inc Shar - GuruFocus
What is Leerink Partnrs’ Forecast for Zymeworks Q1 Earnings? - The AM Reporter
Insiders Are Spending Big: 15 Stocks Leading in March - Insider Monkey
Zymeworks sees over $2.8 million in stock purchases by EcoR1 Capital - Investing.com Australia
Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus PT from Brokerages - Defense World
Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital - Defense World
EcoR1 capital acquires $13.1 million in Zymeworks stock By Investing.com - Investing.com South Africa
EcoR1 capital acquires $13.1 million in Zymeworks stock - Investing.com India
Equities Analysts Issue Forecasts for Zymeworks Q1 Earnings - Defense World
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):